Latest news with #Thermo
Business Wire
22-05-2025
- Health
- Business Wire
Thermo Fisher Scientific Introduces Next Generation TruNarc Handheld Narcotics Analyzers to Support Public Safety
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ TruNarc™ Delta and Tau Handheld Narcotics Analyzers* to help communities combat known and emerging narcotics and illicit substances. With touchless technology and an expanded chemical library, the user-friendly devices empower frontline law enforcement officials to identify more than 1,200 substances in the field, including stimulants, depressants, hallucinogens and analgesics – even at low concentrations or in mixtures – in seconds.** As drug substances continue to evolve and become harder to identify, the on-device chemical library of the TruNarc analyzer is updated regularly to keep pace with new and emerging illicit drug threats. Share Drug overdoses, particularly due to the illicit use of opioids such as fentanyl and methamphetamines, claim the lives of more than 100,000 people in the United States alone each year. Law enforcement officials, in particular, face an increased risk of unintentional exposure and challenges with accurately identifying dangerous substances in the field. The TruNarc analyzers enable law enforcement officials to test substances they seize from a safe distance, helping them stop the flow of drugs across borders and keep narcotics off the streets. 'For nearly a decade, the first generation TruNarc analyzer has been an integral part of our operations and is essential in our fight against the drug epidemic,' said Brian Coen, drug unit detective at the Quincy Police Department in Massachusetts. 'With so many emerging drugs entering our communities, it is imperative to know what we are dealing with right away. With rapid, on-the-spot identification, we can trigger the appropriate response – whether it's making an arrest, leveraging results in criminal proceedings or directing people to relevant rehabilitation programs.' Manufactured in Tewksbury, Mass., the new TruNarc analyzers build on the first generation with an updated industrial design, improved and modernized user interface, and performance enhancements that enable faster results. Automated record keeping generates documentation with complete scan data, including time-and-date stamps, to expedite prosecution and secure legal integrity. As drug substances continue to evolve and become harder to identify, the on-device chemical library of the TruNarc analyzer is updated regularly to keep pace with new and emerging illicit drug threats. 'Since we first introduced the TruNarc analyzer, we've earned the trust of law enforcement officials through reliable performance and proven results,' said Richard McCartney, president of chemical analysis at Thermo Fisher Scientific. 'As the opioid crisis persists, there's a clear need for enhanced tools that better support public safety. By building on our proven technology, we are equipping those in the field with lab-quality tools that are durable enough to be used in a variety of environments.' Law enforcement agencies in all 50 states and in more than 50 countries have adopted the TruNarc analyzer since its introduction to the market in 2012. To learn more about the new TruNarc analyzers, please visit: * The TruNarc Delta Narcotics Analyzer is designed for use within the United States. The TruNarc Tau Narcotics Analyzer is available globally. Both models offer the same trusted performance but are tailored to meet global export requirements. ** Low concentration mixtures may require additional preparation time and the use of a Type H2 test kit to analyze illicit compounds. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
Yahoo
24-04-2025
- Business
- Yahoo
Thermo Fisher Scientific Inc (TMO) Q1 2025 Earnings Call Highlights: Strong Financial ...
Revenue: $10.36 billion for Q1. Adjusted Operating Income: $2.27 billion for Q1. Adjusted Operating Margin: 21.9% for Q1. Adjusted EPS: $5.15 per share, a 1% increase for Q1. GAAP EPS: $3.98, up 15% from Q1 last year. Organic Revenue Growth: 1% for Q1. Free Cash Flow: $370 million for Q1. Cash Flow from Operations: $720 million for Q1. Share Repurchases: $2 billion in Q1. Dividend Increase: 10% in Q1. 2025 Revenue Guidance: $43.3 billion to $44.2 billion. 2025 Adjusted EPS Guidance: $21.76 to $22.84. R&D Expense: $342 million in Q1, 7.5% of manufacturing revenue. Net Interest Expense: Approximately $100 million for Q1. Adjusted Tax Rate: 10% for Q1. Average Diluted Shares: 379 million for Q1. Leverage Ratio: 3.2x gross debt to adjusted EBITDA at end of Q1. Adjusted ROIC: 11.4% for Q1. Life Science Solutions Revenue Growth: 2% organic growth in Q1. Analytical Instruments Revenue Growth: 3% organic growth in Q1. Specialty Diagnostics Revenue Growth: 4% organic growth in Q1. Laboratory Products and Biopharma Services Revenue: Decreased 1% organic in Q1. Warning! GuruFocus has detected 4 Warning Signs with TMO. Release Date: April 23, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Thermo Fisher Scientific Inc (NYSE:TMO) delivered strong financial performance in Q1 2025, with revenue of $10.36 billion and adjusted EPS growth of 1% to $5.15 per share. The company demonstrated excellent execution across all dimensions, translating revenue performance into earnings that exceeded expectations. Thermo Fisher Scientific Inc (NYSE:TMO) launched several innovative products, including the Thermo Scientific Vulcan Automated Lab and the next-generation Thermo Scientific Transcend, enhancing their market leadership. The company continued to strengthen its commercial engine and deepen its trusted partner status with customers, which is expected to accelerate innovation and productivity. Thermo Fisher Scientific Inc (NYSE:TMO) successfully executed its capital deployment strategy, including a $4.1 billion acquisition agreement for Solventum's Purification & Filtration business and $2 billion in share repurchases. Revenue in the Academic and Government segment declined due to macroeconomic conditions in the US and China. The company faced a 3% headwind from the combined impact of two fewer selling days and the runoff of pandemic-related revenue. Thermo Fisher Scientific Inc (NYSE:TMO) updated its 2025 guidance to reflect macroeconomic uncertainties, including tariffs and US policy changes, which are expected to impact revenue and adjusted EPS. The company anticipates a $400 million revenue headwind due to US-China tariffs, affecting sales of US-made products in China. The updated guidance reflects a $500 million reduction in revenue expectations due to policy changes impacting US Academic and Government customers and clinical trials related to vaccines. Q: Given the uncertainty in the broader market and policy changes, how is Thermo Fisher Scientific approaching its guidance methodology? A: Marc Casper, CEO, explained that despite the dynamic macro environment, the company had a strong start to the year. They are fully mobilized on mitigation actions and will capitalize on opportunities as they arise. The guidance reflects current conditions, and they are prepared to adjust as necessary. The upside scenario includes changes in US-China policies, while the downside involves potential tariff increases or macroeconomic impacts. Q: How does Thermo Fisher view the long-term growth prospects of the life sciences tools market, considering potential changes in US government funding and other macro factors? A: Marc Casper, CEO, expressed optimism about the long-term health of the industry, driven by aging populations and scientific breakthroughs. While short-term challenges exist, the fundamental drivers of growth remain strong. The company will continue to assess the situation and adjust its outlook as needed. Q: Are there any changes in order behavior or patterns in the large biopharma end market due to tariffs? A: Marc Casper, CEO, noted that given the short timeframe since the tariff announcements, there hasn't been significant order pull-forward. The company hasn't observed any meaningful changes in customer behavior and expects normal patterns to continue. Q: How flexible is Thermo Fisher's manufacturing in mitigating tariff impacts, and what are the priorities for flexing manufacturing capabilities? A: Stephen Williamson, CFO, explained that the company has a flexible manufacturing system, with scale facilities in every major geography. This allows them to move production efficiently and mitigate tariff impacts. The PPI Business System aids in executing these changes effectively. Q: What impact do policy changes have on Thermo Fisher's guidance, particularly in the Academic and Government and Clinical Research markets? A: Marc Casper, CEO, stated that $200 million of the guidance reduction is due to canceled or delayed vaccine studies in Clinical Research, with the remaining impact from Academic and Government markets. The company expects US Academic to be relatively soft for the rest of the year, with potential improvements based on future appropriations. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Boston Globe
26-02-2025
- Business
- Boston Globe
Bitcoin slides under $90,000, erasing some of the gains made under Trump
LEADERSHIP Unilever ousts chief, elevates CFO in push for faster growth Hein Schumacher. Hollie Adams/Bloomberg Unilever Plc pushed out chief executive Hein Schumacher after less than two years, signaling that the board wasn't satisfied with the pace of restructuring at the maker of Hellmann's mayonnaise and Ben & Jerry's ice cream. The Anglo-Dutch consumer goods company said chief financial officer Fernando Fernandez will take over as CEO on March 1 and hailed his ability to 'drive change at speed,' hinting that the board wants to push Unilever's transformation even faster. — BLOOMBERG NEWS Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up FOOD Advertisement Restaurants warn of potential $12 billion hit from Trump tariffs A cook made scrambled eggs at Miracle Mile Cafe on Feb. 13 in San Rafael, Calif. Justin Sullivan/Getty The US trade group representing restaurants urged President Trump to spare food and drinks from tariffs, estimating the levies could cost the industry more than $12 billion and lead to higher prices for consumers. In a letter to the president, the National Restaurant Association said companies would have no choice but to raise prices if tariffs came into effect, citing the industry's already-tight profit margins of 3 percent to 5 percent on average. Trump pledged during his campaign to tame inflation. 'We urge you to exempt food and beverage products to minimize the impact on restaurant owners and consumers,' the association said in the letter viewed by Bloomberg News. 'This will help keep menu prices stable.' The group estimated the potential impact assuming 25 percent tariffs on food and beverage products from Mexico and Canada. — BLOOMBERG NEWS ACQUISITIONS Thermo Fisher inks $4 billion deal to buy former 3M filtration business Thermo Fisher Scientific is buying 3M's former filtration and purification business for $4.1 billion. John Tlumacki/Globe Staff Thermo Fisher Scientific is growing its lab equipment empire with a deal to buy 3M's former purification and filtration business for $4.1 billion. Waltham-based Thermo is buying the business from Solventum, a Minn.-based company that spun off from manufacturing conglomerate 3M roughly one year ago. The business that Thermo is buying employs about 2,500 people across the globe, and it generated about $1 billion of revenue in 2024. (Thermo, in comparison, reported $43 billion in revenue for the year, and around 125,000 employees.) Thermo said the purchase broadens its product line used for the development and manufacturing of biologic medicines. Aside from the biopharmaceutical sector, the filters and membranes are used in the manufacturing of microelectronics and food products, as well as for cleaning drinking water. The deal is expected to be completed by the end of 2025. Thermo expects to receive $125 million of annual operating income, based on the potential revenue and cost synergies, within five years after the deal closes. Shares in Thermo, the largest public company in Massachusetts based on market value, gained less than 1 percent on Tuesday after the deal was announced, while Solventum's shares were up by more than 9 percent. — JON CHESTO Advertisement SOCIAL MEDIA 277 million more harmful posts could flood Facebook and Instagram, study says Meta's headquarters in Menlo Park, Calif. JASON HENRY/NYT After Mark Zuckerberg's January turnaround on 'free expression,' what's in store for the billions of users of Facebook and Instagram? They could encounter at least 277 million more instances of hate speech and other harmful content each year, according to a new estimate from the Center for Countering Digital Hate (CCDH), a nonprofit that frequently battles social media companies over moderation practices. Last month, Meta announced sweeping changes to the community guidelines that define what sorts of speech it does and doesn't allow. The company said it would shift how it enforces many of its rules and ratchet back limits to speech targeting women, LGBTQ+ people, immigrants, and other marginalized groups. The main driver for a potential surge in hate speech, CCDH said, is an important change to how Meta says it will identify some harmful content: relying on users to report it rather than automated systems to take it down. — WASHINGTON POST Advertisement LEGAL Farmers sue USDA after agency deletes climate change data The US Department of Agriculture building in Washington. Jose Luis Magana/Associated Press A group of farmers and environmental nonprofits sued the US Department of Agriculture, accusing the agency of scrubbing data relating to climate change from its website and saying the move would hinder research and hurt farming initiatives. In a lawsuit filed Monday in the US District Court for the Southern District of New York, the Northeast Organic Farming Association of New York (NOFA-NY) and two environmental nonprofits, the Natural Resources Defense Council and the Environmental Working Group, accused the USDA of deleting 'climate-related policies, guides, datasets, and resources from its websites' in violation of laws on government transparency and agency action. The suit said the agency's actions hurt farmers who used the data to plan 'agricultural decisions' and access funding, made it more difficult for climate researchers and advocates to do their jobs and 'deprived the public' of 'vital information.' — WASHINGTON POST TECH Microsoft workers protest sale of AI and cloud services to Israeli military Microsoft CEO Satya Nadella at the Microsoft Ignite conference on Nov. 19, 2024, in Chicago. Charles Rex Arbogast/Associated Press Five Microsoft employees were ejected from a meeting with the company's chief executive for protesting contracts to provide artificial intelligence and cloud computing services to the Israeli military. The protest on Monday came after an investigation by the Associated Press revealed last week that sophisticated AI models from Microsoft and OpenAI had been used as part of an Israeli military program to select bombing targets during the recent wars in Gaza and Lebanon. The story also contained details of an errant Israeli airstrike in 2023 that struck a vehicle carrying members of a Lebanese family, killing three young girls and their grandmother. Microsoft CEO Satya Nadella was speaking about new products at an employee town hall meeting at the company's corporate campus in Redmond, Wash. Workers standing about 15 feet to his right then revealed T-shirts that when they stood side-by-side spelled out the question 'Does Our Code Kill Kids, Satya?' Photos and video of the incident, which was live streamed throughout the company, shows Nadella kept speaking and did not acknowledge the protesters. Two men quickly tapped the workers on the shoulders and ushered them out of the room. — ASSOCIATED PRESS Advertisement AUTOMOTIVE Tesla sales fall 45 percent in Europe amid Musk's political meddling A Tesla electric car dealership in Erfurt, Germany. Sean Gallup/Getty Tesla Inc.'s sales plunged 45 percent last month across Europe, where rival carmakers saw a surge in electric-vehicle demand. The Elon Musk-led company registered only 9,945 cars in January, down from 18,161 a year ago, according to the European Automobile Manufacturers' Association. EV sales soared 37 percent for the overall industry, with carmakers posting big gains in Germany and the UK. Tesla shares fell 8.4 percent Tuesday in New York, sending the company's market value back below $1 trillion. The stock has tumbled 25 percent this year. Tesla is changing over production lines for by far its most popular vehicle, the Model Y SUV, and contending with its chief executive becoming an increasingly polarizing figure in global politics. After emerging as a leading donor to Donald Trump during last year's US election cycle, Musk set his sights on Europe, backing far-right parties and attacking incumbents. — BLOOMBERG NEWS HEALTH COVID-like bat virus discovered by researchers in Chinese lab An infectious diseases research team caught bats for a study outside the Khao Chong Phran Cave in Ratchaburi, Thailand, in 2020. ADAM DEAN/NYT Researchers at the Wuhan Institute of Virology in China said they discovered a new coronavirus in bats that enters cells using the same gateway as the virus that causes COVID-19. This virus hasn't been detected in humans, merely identified in a laboratory. Word of the discovery lifted the shares of some vaccine makers Friday. Moderna Inc. rose as much as 6.6 percent Friday afternoon and Novavax Inc. rose as much as 7.8 percent. American depositary receipts of BioNTech SE, Pfizer Inc.'s COVID vaccine partner, climbed as much as 5.1 percent. Pfizer gained as much as 2.6 percent. The lab finding does raise the possibility that this new bat virus could spread from animals to humans, researchers said in a paper published Tuesday in the journal Cell. — BLOOMBERG NEWS Advertisement
